Benefits and safety of gabapentinoids in chronic low back pain: A systematic review and meta-analysis of randomized controlled trials

Harsha Shanthanna, Ian Gilron, Manikandan Rajarathinam, Rizq AlAmri, Sriganesh Kamath, Lehana Thabane, Philip J Devereaux, Mohit Bhandari, Harsha Shanthanna, Ian Gilron, Manikandan Rajarathinam, Rizq AlAmri, Sriganesh Kamath, Lehana Thabane, Philip J Devereaux, Mohit Bhandari

Abstract

Background and objective: Chronic Low Back Pain (CLBP) is very common, with a lifetime prevalence between 51% and 80%. In majority, it is nonspecific in nature and multifactorial in etiology. Pregabalin (PG) and Gabapentin (GB) are gabapentinoids that have demonstrated benefit in neuropathic pain conditions. Despite no clear rationale, they are increasingly used for nonspecific CLBP. They necessitate prolonged use and are associated with adverse effects and increased cost. Recent guidelines from the National Health Service (NHS), England, expressed concerns on their off-label use, in addition to the risk of misuse. We aimed to assess the effectiveness and safety of gabapentinoids in adult CLBP patients.

Methods: Electronic databases of MEDLINE, EMBASE, and Cochrane were searched from their inception until December 20th, 2016. We included randomized control trials reporting the use of gabapentinoids for the treatment of CLBP of >3 months duration, in adult patients. Study selection and data extraction was performed independently by paired reviewers. Outcomes were guided by Initiative on Methods, Measurement and Pain Assessment in Clinical Trials guidelines, with pain relief and safety as the primary outcomes. Meta-analyses were performed for outcomes reported in 3 or more studies. Outcomes were reported as mean differences (MDs) or risk ratios (RRs) with their corresponding 95% confidence intervals (CIs), and I2 in percentage representing the percentage variability in effect estimates that could be explained by heterogeneity. GRADE (Grading of Recommendations Assessment, Development, and Evaluation) was used to assess the quality of evidence.

Results: Out of 1,385 citations, eight studies were included. Based on the interventions and comparators, studies were analyzed in 3 different groups. GB compared with placebo (3 studies, n = 185) showed minimal improvement of pain (MD = 0.22 units, 95% CI [-0.5 to 0.07] I2 = 0%; GRADE: very low). Three studies compared PG with other types of analgesic medication (n = 332) and showed greater improvement in the other analgesic group (MD = 0.42 units, 95% CI [0.20 to 0.64] I2 = 0; GRADE: very low). Studies using PG as an adjuvant (n = 423) were not pooled due to heterogeneity, but the largest of them showed no benefit of adding PG to tapentadol. There were no deaths or hospitalizations reported. Compared with placebo, the following adverse events were more commonly reported with GB: dizziness-(RR = 1.99, 95% CI [1.17 to 3.37], I2 = 49); fatigue (RR = 1.85, 95% CI [1.12 to 3.05], I2 = 0); difficulties with mentation (RR = 3.34, 95% CI [1.54 to 7.25], I2 = 0); and visual disturbances (RR = 5.72, 95% CI [1.94 to 16.91], I2 = 0). The number needed to harm with 95% CI for dizziness, fatigue, difficulties with mentation, and visual disturbances were 7 (4 to 30), 8 (4 to 44), 6 (4 to 15), and 6 (4 to 13) respectively. The GRADE evidence quality was noted to be very low for dizziness and fatigue, low for difficulties with mentation, and moderate for visual disturbances. Functional and emotional improvements were reported by few studies and showed no significant improvements.

Conclusions and relevance: Existing evidence on the use of gabapentinoids in CLBP is limited and demonstrates significant risk of adverse effects without any demonstrated benefit. Given the lack of efficacy, risks, and costs associated, the use of gabapentinoids for CLBP merits caution. There is need for large high-quality trials to more definitively inform this issue.

Trial registration: PROSPERO CRD42016034040.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1. PRISMA flow diagram.
Fig 1. PRISMA flow diagram.
Fig 2. RoB within the included studies.
Fig 2. RoB within the included studies.
RoB, risk of bias.
Fig 3. Analyses of pain relief with…
Fig 3. Analyses of pain relief with GB or PG in patients with CLBP.
CLBP, chronic low back pain; GB, gabapentin; IV, intravenous; M-H, Mantel-Haenszel; PG, pregabalin.
Fig 4. Analyses of adverse effects observed…
Fig 4. Analyses of adverse effects observed with GB or PG in CLBP.
CLBP, chronic low back pain; GB, gabapentin; IV, intravenous; M-H, Mantel-Haenszel; PG, pregabalin.

References

    1. Deyo RA, Weinstein JN. Low back pain. The New England journal of medicine. 2001;344(5):363–70. doi:
    1. Hooten WM, Cohen SP. Evaluation and Treatment of Low Back Pain: A Clinically Focused Review for Primary Care Specialists. Mayo Clin Proc. 2015;90(12):1699–718. doi:
    1. Hoy D, Bain C, Williams G, March L, Brooks P, Blyth F, et al. A systematic review of the global prevalence of low back pain. Arthritis Rheum. 2012;64(6):2028–37. doi:
    1. Morlion B. Chronic low back pain: pharmacological, interventional and surgical strategies. Nature reviews Neurology. 2013;9(8):462–73. doi:
    1. Shanthanna H, Gilron I, Thabane L, Devereaux PJ, Bhandari M, AlAmri R, et al. Gabapentinoids for chronic low back pain: a protocol for systematic review and meta-analysis of randomised controlled trials. BMJ open. 2016;6(11).
    1. Chou R, Huffman LH. Medications for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline. Ann Intern Med. 2007;147(7):505–14.
    1. White AP, Arnold PM, Norvell DC, Ecker E, Fehlings MG. Pharmacologic management of chronic low back pain: synthesis of the evidence. Spine. 2011;36(21 Suppl):S131–43.
    1. Patel R, Dickenson AH. Mechanisms of the gabapentinoids and alpha 2 delta-1 calcium channel subunit in neuropathic pain. Pharmacol Res Perspect. 2016;4(2):e00205 doi:
    1. Maizels M, McCarberg B. Antidepressants and antiepileptic drugs for chronic non-cancer pain. Am Fam Physician. 2005;71(3):483–90.
    1. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev. 2009(3):Cd007076 doi:
    1. Chaparro LE, Smith SA, Moore RA, Wiffen PJ, Gilron I. Pharmacotherapy for the prevention of chronic pain after surgery in adults. Cochrane Database Syst Rev. 2013(7):Cd008307 doi:
    1. Mack A. Examination of the evidence for off-label use of gabapentin. J Manag Care Pharm. 2003;9(6):559–68. doi:
    1. Public Health England and National Health Services, UK. Advice for prescribers on the risk of the misuse of pregabalin and gabapentin. . First published 14 December 2014. Last accessed 22 January, 2017.
    1. Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005;113(1–2):9–19. doi:
    1. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. International journal of surgery (London, England). 2010;8(5):336–41.
    1. Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. Family medicine. 2005;37(5):360–3.
    1. Schandelmaier S, Ebrahim S, Burkhardt SC, de Boer WE, Zumbrunn T, Guyatt GH, et al. Return to work coordination programmes for work disability: a meta-analysis of randomised controlled trials. PLoS ONE. 2012;7(11):e49760 doi:
    1. Higgins JPT G S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 The Cochrane Collaboration: The Cochrane Collaboration; 2011. Last accessed 22 January 2017.
    1. Chan AW, Altman DG. Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors. BMJ (Clinical research ed). 2005;330(7494):753.
    1. Andrew Moore R, Eccleston C, Derry S, Wiffen P, Bell RF, Straube S, et al. "Evidence" in chronic pain—establishing best practice in the reporting of systematic reviews. Pain. 2010;150(3):386–9.
    1. Ioannidis JP, Cappelleri JC, Lau J. Issues in comparisons between meta-analyses and large trials. Jama. 1998;279(14):1089–93.
    1. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. Journal of clinical epidemiology. 2000;53(11):1119–29.
    1. Ebrahim S, Johnston BC, Akl EA, Mustafa RA, Sun X, Walter SD, et al. Addressing continuous data measured with different instruments for participants excluded from trial analysis: a guide for systematic reviewers. J Clin Epidemiol 2014. May;67(5):560–70. doi:
    1. Akl EA, Johnston BC, Alonso-Coello P, Neumann I, Ebrahim S, Briel M, et al. Addressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewers. PLoS ONE. 2013;8(2):e57132 doi:
    1. Atkinson JH, Slater MA, Capparelli EV, Patel SM, Wolfson T, Gamst A, et al. A randomized controlled trial of gabapentin for chronic low back pain with and without a radiating component. Pain. 2016;157(7):1499–507. doi:
    1. McCleane GJ. Gabapentin reduces chronic benign nociceptive pain: a double-blind, placebo-controlled cross-over study. The Pain Clinic. 2000;12(2):81–5.
    1. McCleane GJ. Does gabapentin have an analgesic effect on background, movement and referred pain? A randomised, double-blind, placebo controlled study. The Pain Clinic. 2001;13(2):103–7.
    1. Baron R, Martin-Mola E, Muller M, Dubois C, Falke D, Steigerwald I. Effectiveness and Safety of Tapentadol Prolonged Release (PR) Versus a Combination of Tapentadol PR and Pregabalin for the Management of Severe, Chronic Low Back Pain With a Neuropathic Component: A Randomized, Double-blind, Phase 3b Study. Pain Pract. 2015;15(5):455–70. doi:
    1. Kalita J, Kohat AK, Misra UK, Bhoi SK. An open labeled randomized controlled trial of pregabalin versus amitriptyline in chronic low backache. J Neurol Sci. 2014;342(1–2):127–32. doi:
    1. Pota V, Barbarisi M, Sansone P, Moraci M, Pace MC, Passavanti MB, et al. Combination therapy with transdermal buprenorphine and pregabalin for chronic low back pain. Pain Manag. 2012;2(1):23–31. doi:
    1. Romano CL, Romano D, Bonora C, Mineo G. Pregabalin, celecoxib, and their combination for treatment of chronic low-back pain. J Orthop Traumatol. 2009;10(4):185–91. doi:
    1. Sakai Y, Ito K, Hida T, Ito S, Harada A. Pharmacological management of chronic low back pain in older patients: a randomized controlled trial of the effect of pregabalin and opioid administration. European spine journal: official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society. 2015;24(6):1309–17.
    1. Morlion B. Pharmacotherapy of low back pain: targeting nociceptive and neuropathic pain components. Current medical research and opinion. 2011;27(1):11–33. doi:
    1. Chiappini S, Schifano F. A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency's 'Suspected Adverse Drug Reactions' Database. CNS drugs. 2016;30(7):647–54. doi:
    1. Bezerra DM, El Dib R, Vidal EIO, De Barros GAM, Chou R, Fukushima F. Anticonvulsants for chronic low-back pain. Cochrane Database of Systematic Reviews. 2014(6). CD011171
    1. Tetsunaga T, Tetsunaga T, Tanaka M, Sugimoto Y, Takigawa T, Ozaki T. Outcomes of pregabalin in lumbar-disease patients with depression. Journal of orthopaedic science: official journal of the Japanese Orthopaedic Association. 2014;19(2):229–34.
    1. Sakai Y, Ito K, Hida T, Ito S, Harada A. Neuropathic pain in elderly patients with chronic low back painand effects of pregabalin: a preliminary study. Asian spine journal. 2015;9(2):254–62. doi:
    1. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162–73. doi:
    1. Simunovic M, Baxter NN. Knowledge translation research: a review and new concepts from a surgical case study. Surgery. 2009;145(6):639–44. doi:
    1. Giladi H, Choinière M, Fitzcharles M-A, Ware MA, Tan X, Shir Y. Pregabalin for chronic pain: does one medication fit all? Current medical research and opinion. 2015;31(7):1403–11. doi:
    1. Baron R, Binder A, Attal N, Casale R, Dickenson AH, Treede RD. Neuropathic low back pain in clinical practice. Eur J Pain. 2016; 20(6): 861–873. doi:
    1. Taguchi T, Igarashi A, Watt S, Parsons B, Sadosky A, Nozawa K, et al. Effectiveness of pregabalin for the treatment of chronic low back pain with accompanying lower limb pain (neuropathic component): a non-interventional study in Japan. J Pain Res. 2015;8:487–97. doi:
    1. Orita S, Yamashita M, Eguchi Y, Suzuki M, Inoue G, Miyagi M, et al. Pregabalin for Refractory Radicular Leg Pain due to Lumbar Spinal Stenosis: A Preliminary Prospective Study. Pain Research and Management. 2016;2016:10.
    1. Baron R, Freynhagen R, Tolle TR, Cloutier C, Leon T, Murphy TK, et al. The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy. Pain. 2010;150(3):420–7. doi:
    1. Markman JD, Frazer ME, Rast SA, McDermott MP, Gewandter JS, Chowdhry AK, et al. Double-blind, randomized, controlled, crossover trial of pregabalin for neurogenic claudication. Neurology. 2015;84(3):265–72. doi:
    1. Cohen SP, Hanling S, Bicket MC, White RL, Veizi E, Kurihara C, et al. Epidural steroid injections compared with gabapentin for lumbosacral radicular pain: multicenter randomized double blind comparative efficacy study. BMJ: British Medical Journal. 2015;350:h1748 doi:
    1. Thorlund K, Imberger G, Johnston BC, Walsh M, Awad T, Thabane L, et al. Evolution of heterogeneity (I2) estimates and their 95% confidence intervals in large meta-analyses. PLoS ONE. 2012;7(7):e39471 doi:
    1. Muehlbacher M, Nickel MK, Kettler C, Tritt K, Lahmann C, Leiberich PK, et al. Topiramate in treatment of patients with chronic low back pain: a randomized, double-blind, placebo-controlled study. Clin J Pain. 2006;22(6):526–31.
    1. Spence D. Bad medicine: gabapentin and pregabalin. BMJ (Clinical research ed). 2013;347:f6747.
    1. Mathieson S, Maher CG, McLachlan AJ, Latimer J, Koes BW, Hancock MJ, et al. PRECISE—pregabalin in addition to usual care for sciatica: study protocol for a randomised controlled trial. Trials. 2013;14(1):213.
    1. Clinical Trials Registry. . Last accessed 22 January, 2017.
    1. Clinical Trials Registry. . Last accessed 22 January, 2017.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel